elenestinib
elenestinib: developed by 1 company · 3 clinical trials tracked.
elenestinib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could elenestinib → BPMC affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Blueprint Medicines Corp (BPMC) Indolent Systemic Mastocytosis; Healthy Participants | Phase 2/Phase 3 |
Clinical Trials (3)
A Phase 1, Open-Label Study to Evaluate the Effect of Elenestinib on the Pharmacokinetics of Midazolam and Combined Oral Contraceptives, Levonorgestrel/Ethinyl Estradiol, in Healthy Adult Female Participants
Primary endpoint: Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t)
A Phase 1/2, Open-label, 2-arm Study Evaluating BLU-263 as Monotherapy and in Combination With Azacitidine, in Patients With KIT Altered Hematologic Malignancies
Primary endpoint: Dose Escalation: Number of Dose-limiting Toxicities (DLTs) (monotherapy only)
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Primary endpoint: Part 1: Number of participants with Treatment-emergent Adverse Events (TEAEs)
Frequently asked questions
Who is developing elenestinib?
elenestinib is being developed by Blueprint Medicines Corp.
How many clinical trials involve elenestinib?
BioSniper tracks 3 clinical trials involving elenestinib.